What is VitaDAO?
VitaDAO operates as a Decentralized Autonomous Organization (DAO) dedicated to community-governed and decentralized drug development. Its primary objective is to accelerate research and development (R&D) within the longevity sector, aiming to extend human life and healthspan. The organization achieves this by collectively funding and digitizing research through the use of IP-NFTs, and subsequently spinning out new biotech companies from these initiatives.
How much funding has VitaDAO raised?
VitaDAO has raised a total of $4.1M across 1 funding round:
Other Financing Round
$4.1M
Other Financing Round (2023): $4.1M with participation from L1 Digital, Pfizer Ventures, and Shine Capital
Key Investors in VitaDAO
L1 Digital
L1 Digital implements investments through crypto-native managers, co-investments, and direct strategies, indicating a focus on digital asset markets.
Pfizer Ventures
Pfizer Ventures is the venture capital arm of Pfizer, likely focusing on strategic investments in companies that align with Pfizer's pharmaceutical and healthcare interests.
Shine Capital
Shine Capital is an early-stage venture capital firm that partners with innovative entrepreneurs to build iconic businesses, with a focus on early-stage ventures.
What's next for VitaDAO?
The substantial enterprise-level funding and strategic investment position VitaDAO for accelerated growth and expanded R&D initiatives. This capital infusion is expected to fuel the development of new longevity-focused biotech ventures and further solidify its role in advancing decentralized drug discovery. The company's focus on IP-NFTs suggests a strategic move towards creating novel, digitally native assets for intellectual property within the biotech space, potentially attracting further investment and partnerships.
See full VitaDAO company page
